Review





Similar Products

fhd 286  (MedChemExpress)
94
MedChemExpress fhd 286
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Fhd 286, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/Camibirstat/bio_rxiv__64898__2026__05__22__726988-282-10-11
Average 94 stars, based on 1 article reviews
fhd 286 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
fhd 609  (MedChemExpress)
93
MedChemExpress fhd 609
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Fhd 609, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/FHD-609/pm41237357-61-11-12
Average 93 stars, based on 1 article reviews
fhd 609 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
framingham heart disease fhd  (Kaggle Inc)
86
Kaggle Inc framingham heart disease fhd
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Framingham Heart Disease Fhd, supplied by Kaggle Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/dataset+framingham/10__1007_slash_s10462___025___11385___6-299-28-32
Average 86 stars, based on 1 article reviews
framingham heart disease fhd - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
toupcamtm fhd camera  (Photonics Inc)
86
Photonics Inc toupcamtm fhd camera
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Toupcamtm Fhd Camera, supplied by Photonics Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/camera+fhd+toupcamtm/bio_rxiv__2025__08__29__673164-31-4-8
Average 86 stars, based on 1 article reviews
toupcamtm fhd camera - by Bioz Stars, 2026-09
86/100 stars
  Buy from Supplier
paper n a fhd 286 medchemexpress  (MedChemExpress)
94
MedChemExpress paper n a fhd 286 medchemexpress
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Paper N A Fhd 286 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/FHD-286/pm40695292-164-249-252
Average 94 stars, based on 1 article reviews
paper n a fhd 286 medchemexpress - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
hy 144835 au 15330 medchemexpress  (MedChemExpress)
94
MedChemExpress hy 144835 au 15330 medchemexpress
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Hy 144835 Au 15330 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/FHD-286/pm40695292-164-254-256
Average 94 stars, based on 1 article reviews
hy 144835 au 15330 medchemexpress - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
fhd  (MedChemExpress)
94
MedChemExpress fhd
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Fhd, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/FHD-286/bio_rxiv__2025__07__08__661805-129-0-14
Average 94 stars, based on 1 article reviews
fhd - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
fhd zip camera  (TAGARNO AS)
90
TAGARNO AS fhd zip camera
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Fhd Zip Camera, supplied by TAGARNO AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/fhd+zip+camera/10__1016_slash_j__ohx__2025__e00666-77-6-6
Average 90 stars, based on 1 article reviews
fhd zip camera - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
digital microscope zip fhd  (TAGARNO AS)
90
TAGARNO AS digital microscope zip fhd
(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, <t>FHD-286.</t> IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.
Digital Microscope Zip Fhd, supplied by TAGARNO AS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fhd/digital+microscope+fhd+trend/pm40372507-27-11-14
Average 90 stars, based on 1 article reviews
digital microscope zip fhd - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, FHD-286. IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.

Journal: bioRxiv

Article Title: Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States

doi: 10.64898/2026.05.22.726988

Figure Lengend Snippet: (A) Pseudotime determined by Monocle 3 is projected onto the snRNA-seq UMAP. A trajectory was noted between clusters 7 (SMC) and 8 (MES). (B) Stacked bar graph demonstrating distribution of cells from individual tumors in different colors in clusters 7 and 8, demonstrating that many of the tumors in the cohort have a population of cells from both clusters 7 and 8. (C) Western blots demonstrating depletion of FOSL2 and subsequent enrichment in mesenchymal markers (ZEB1, NCAM1, vimentin) in an SMC cell line (Leio-012). (D) Western blots demonstrating depletion of NFIX and subsequent decrease of mesenchymal markers (ZEB1, NCAM1) and increase in smooth muscle markers (SMA, MKL1) in a MES cell line (SK-UT-1B). (E) CUT&RUN was performed to assess pathways controlled by each TF. (E) Enrichment of peaks centered on NFIX peaks identified from CUT&RUN data in SK-UT-1B. (F) Venn diagrams showing overlap of peaks identified from CUT&RUN in SK-UT-1B. (G) IGV tracks in a representative MES-defining gene showing the presence of NFIX but absence of FOSL2. (H) Enrichment of peaks centered on FOSL2 peaks identified from CUT&RUN data in Leio-012. (I) Venn diagrams showing overlap of peaks identified from CUT&RUN in Leio-012. (J) IGV tracks in a representative SMC-defining gene showing the presence of FOSL2 but absence of NFIX. (K) Dose response curves with treatment with the SMARCA4/2 inhibitor, FHD-286. IC50 values are shown on the right. (N) Western blots after immunoprecipitating NFIX from SK-UT-1B cells. (L-M) Tumor volume measurements following xenografting of SK-UT-1B (L) and SK-LMS-1 (M) into immunodeficient nude mice and treatment with FHD-286, 1.5 mg/kg given by oral gavage, days 1-5 of 7-day cycles. Treatment started at day 0 on the graph following tumor growth to 100-200 mm 3 . N = 5 mice per group. ***P value < 0.001. (N) Apoptosis assay was performed by staining cells with anti-Annexin V and propidium iodide following treatment with a range of concentrations of FHD-286. Bars represent means ± SEM. (O) Western blotting for smooth muscle (SMA) and mesenchymal (Slug) markers in SK-LMS-1 cells treated with FHD-286. (P) NFIX was immunoprecipitated from SK-UT-1B nuclear extracts and probed for other NFI TFs, SWI/SNF components (SMARCA4/2) and the PRC2 component EED as a negative control.

Article Snippet: Chemicals used in this study include: puromycin (InvivoGen), polybrene (InvivoGen), FHD-286 (MedChemExpress), panobinostat (MedChemExpress), vorinostat (MedChemExpress), tazemetostat (MedChemExpress), azacitidine (MedChemExpress), decitabine (MedChemExpress), A-845 (MedChemExpress), JQ1 (MedChemExpress), ZEN-3694 (MedChemExpress), bomedemstat (MedChemExpress), SNDX-5613 (MedChemExpress), MI-503 (MedChemExpress), gintemetostat (MedChemExpress), GSK-J4 (MedChemExpress).

Techniques: Western Blot, Apoptosis Assay, Staining, Immunoprecipitation, Negative Control